Home›Companies›Biotech & Pharma›AcuraStem

AcuraStem Inc

Develops treatments for people with ALS, frontotemporal dementia and other neurodegenerative diseases.

Updated Nov 10, 2026·Latest SEC filing Jun 22, 2026·Suggest an edit

About AcuraStem

AcuraStem is a private company based in Pasadena, California. It has reported $3,890,332 raised in four offerings on Form D since July 2018. Its chief executive is Samuel Alworth.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Not yetJun 22, 2026$0of $5.0M target0—Options, Securities on exercise, Convertible promissory noteRule 506(b)Form D ↗
Nov 21, 2022Nov 30, 2022$3,110,332fully sold1$3.1MOptions, Securities on exercise, Convertible Promissory NoteRule 506(b)Form D ↗
Nov 11, 2022Nov 22, 2022$400,000of $3.5M target1$400KOptions, Securities on exercise, Convertible Promissory NotesRule 506(b)Form D ↗
Jun 20, 2018Jul 12, 2018amended Jun 19, 2019$380,000of $2.0M target1$380KOptions, Securities on exercise, Convertible Promissory NotesRule 506(b)Form D/A ↗1 earlier filing
Total, four offerings$3,890,332

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on AcuraStem's Form D filed Jun 22, 2026.

Samuel Alworth
Samuel Alworth
Co-founder and CEO, director
Paul August
Paul August
Co-founder and director
Marcel van der Brug
Marcel van der Brug
Chief Scientific Officer
Justin Ichida
Justin Ichida
Co-founder and director

Sources

  1. SECAcuraStem Inc Form D, filed Jul 12, 2018
  2. SECAcuraStem Inc filing history
  3. CompanyAbout AcuraStem
  4. CompanyAcuraStem patient-based drug discovery